Table 3.
Biochemical and histological response at week 48-52.
| Normalization of ALT | Improvement in Histology | |||
| Drug | HBeAg+ CHB (%) | HBeAg-CHB (%) | HBeAg+ CHB (%) | HBeAg-CHB (%) |
| Peginterferon | 39 | 38 | 38 | 48 |
| Lamivudine | 66 | 74 | 59 | 63 |
| Adefovir | 48 | 72 | 53 | 64 |
| Entecavir | 68 | 78 | 72 | 70 |
| Telbivudine | 77 | 74 | 65 | 66 |
| Tenofovir | 69 | 77 | 74 | 72 |
| Placebo | 21 | 24 | 25 | 28 |
Tenofovirdata was derived from Marcellin et al. and Heathcote et al. AASLD 2007 Abstract nos. LB2 and LB6, respectively. ALT, alanine aminotransferase, CHB, chronic hepatitis B.